

## Letter to the Editor

Patricia Rodríguez-Lorenzo<sup>1</sup>  
Marta Arias-Temprano<sup>2</sup>  
Alejandra Méndez-Sánchez<sup>1</sup>  
Carlos Pérez-Méndez<sup>1</sup>

# Response to "The importance of an early gastroenteritis diagnosis to discard MIS-C during SARS-CoV-2 pandemic"

<sup>1</sup>Servicio de Pediatría. Hospital Universitario de Cabueñes (Gijón). Asturias.  
<sup>2</sup>Servicio de Microbiología. Hospital Universitario de Cabueñes (Gijón)

### Article history

Received: 27 October 2022; Accepted: 4 January 2023; Published: 3 March 2023

Sir,

We read the interesting paper by Fernández-Miaja et al. where they report four cases of *Campylobacter jejuni* infection in patients with an initial diagnostic suspicion of multiinflammatory syndrome in children (MIS-C) and highlight the importance of ruling out other potential diagnosis in order to avoid unnecessary diagnostic tests and treatment [1]. Interestingly, two of their cases showed marked lymphopenia ( $<1000/\text{mm}^3$ ), one of them with associated elevated C-reactive protein values. American College of Rheumatology guidelines recommend a complete diagnostic evaluation to rule out MIS-C in children with unremitting fever, suggestive clinical features, elevated acute phase reactants and at least one among several laboratory features, including an absolute lymphocyte count below  $1000/\text{mm}^3$  in the absence of other causes that could explain the clinical picture [2]. One study in search of red flags that might help discriminate between MIS-C and other common febrile conditions in children, found that absolute lymphopenia and an elevated C-reactive protein serum concentration were associated with a higher risk of MIS-C [3].

Does *Campylobacter* infection alone explain the association of fever, elevated C-reactive protein values and absolute lymphopenia? Can a child with these findings be safely sent home if a *Campylobacter* PCR test is positive or might a short period of observation in the hospital still be advisable?

We reviewed the clinical files of 110 children younger than 14 years of age with a diagnosis of *Campylobacter* infection seen in our hospital from January 1<sup>st</sup>2017 to June 1<sup>st</sup>2022 and compared the frequency of cases showing both elevated C-reactive protein and lymphopenia before (up to January 2020) and after the start of SARS-CoV-2 pandemic (from January 2020 onwards).

Results are shown in Table 1. As expected, more cases of *Campylobacter* infection were diagnosed in the first period while more laboratory studies were performed in the second period (47.2% vs 14.9%), probably as a reflection of the fear of missing a possible diagnosis of MIS-C in the pandemic era. No cases showing both elevated C-reactive protein and profound lymphopenia were observed among the 74 children seen in the pre-pandemic period, while four (11.1% of the total cases and 30.6% of those in whom laboratory tests were performed) were found in the pandemic era. Evidence of SARS-CoV-2 exposure in the previous weeks was confirmed in three of these cases and infection was documented in one child, who was initially diagnosed as possible MIS-C and treated with intravenous gammaglobulin and corticosteroids for one day; treatment was suspended when the diagnosis of *Campylobacter* infection was confirmed. Clinical characteristics and laboratory findings of these four patients are shown in table 2.

Our results raise the question of whether *Campylobacter* infection alone can be accountable for these laboratory findings and if a positive stool test can safely rule out a diagnosis of MIS-C or a short observation period in the hospital would be prudent, as children with MIS-C may develop additional organ system involvement over the course of admission [4]. Lymphopenia has been previously described in up to 11% of patients with *Campylobacter* infection returning from the tropics,

Table 1

Comparison between the two periods.

Time interval	<i>Campylobacter</i> infection cases	Positive study*	Negative study	No studies performed
2017-2019	74	0	11	63
2020-2022	36	4	13	19

\*Positive study: C-reactive protein  $>30 \text{ mg/L}$  AND absolute lymphocyte count  $<1000/\text{mm}^3$

Patricia Rodríguez Lorenzo.  
Servicio de Pediatría. Hospital Universitario de Cabueñes (Gijón).  
C/ Los Prados 395, 33394 Gijón (Asturias).  
E-mail: patrilorenzo@hotmail.com

Characteristic	Patient 1	Patient 2	Patient 3	Patient 4
<b>Table 2 Patient characteristics and laboratory findings of the four patients with fever, lymphopenia and elevated acute phase reactants associated with <i>Campylobacter</i> infection.</b>				
<b>Demographic</b>				
Sex	Female	Female	Male	Female
Patient age (years)	8	9	12	11
<b>SARS-CoV-2</b>				
Exposure	No	Yes (1 month earlier)	Yes (3 weeks earlier)	Yes (3 months earlier)
Infection	No	No	Yes (2 weeks earlier)	No
<b>Presenting symptoms</b>				
Days of fever at presentation	2	1	1	3
Abdominal pain	Yes	Yes	Yes	Yes
Vomiting	Yes	Yes	No	No
Diarrhea	Yes	No	Yes	Yes
Generalized myalgia	No	No	Yes	Yes
<b>Laboratory values</b>				
WBC/ml	6360	7780	11800	8960
Neutrophils/ml	5400	5930	9959	7350
Lymphocytes/ml	680	920	800	970
Hemoglobin (g/dl)	13,5	13,4	13,2	12,6
Platelets/ml	281000	108000	191000	228000
C-Reactive Protein (mg/L)	97	208	116	36
Procalcitonin (ng/ml)	ND	1,27	1,24	ND
SARS-CoV-2 RT PCR	Negative	Negative	Negative	Negative
Stool culture	<i>Campylobacter jejuni</i>	<i>Campylobacter jejuni</i>	<i>Campylobacter jejuni</i> and <i>Yersinia enterocolitica</i>	<i>Campylobacter jejuni</i>
<b>Disposal and Treatment</b>				
Disposal	Admission (Surgery)	Admission Pediatric Intensive Care Unit	Admission Pediatric Ward	Discharged Home
Treatment	Appendectomy Azithromycin	Azithromycin	Corticosteroids and intravenous gammaglobulin (1 day); azithromycin	None

RT-PCR: Reverse transcription polymerase chain reaction. SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2. WBC: White blood cells.

but higher cut-off points to define lymphopenia were used in that study [5]. In a previous series of five cases of bacterial enteritis (4 *Salmonella* species, one *Campylobacter* species) mimicking MIS-C [4], although four patients had mild lymphopenia, none had an absolute count less than 1000 lymphocytes/mm<sup>3</sup>.

Our study has several limitations, including the small number of cases, its retrospective nature, the low frequency of laboratory tests in the prepandemic period, the lack of data on SARS-CoV-2 infection in most of our patients, and the lack of serologic studies regarding their SARS-CoV-2 status, and larger

prospective studies may shed light upon this subject.

## FUNDING

None to declare

## CONFLICT OF INTEREST

Authors declare have no conflict of interest

## REFERENCES

1. Fernández-Miaja M, Vivanco-Allende A, Delgado-Nicolás, S, Llaneza-Velasco ME, Fernández-Domínguez J. The importance of an early gastroenteritis diagnosis to discard MIS-C during SARS-CoV-2 pandemic. *Rev Esp Quimioter* 2022;35(4):406-7. DOI: 10.37201/req/170.2021
2. Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children associated with SARS-CoV-2 and hyperinflammation in pediatric Covid-19: Version 3. *Arthritis Rheumatol*. 2022 Apr;74(4):e-e20. DOI: 10.1002/art.42062.Epub 2022 Feb 3.
3. Carlin RF, Fischer AM, Pitkowsky Z, Abel D, Sewell TB, Landau EG, et al. Discriminating Multisystem Inflammatory Syndrome in children requiring treatment from common febrile conditions in outpatient settings. *J Pediatr* 2021;229:26-32. DOI: 10.1016/j.jpeds.2020.10.013.
4. Dworsky ZD, Roberts JE, Son, MBF, Tremoulet AH, Newburger JW, Burns JC. Mistaken MIS-C: a case series of bacterial enteritis mimicking MIS-C. *Pediatr Infect Dis J* 2021;40 (4):e159-e161. DOI: 10.1097/INF.0000000000003050.
5. Herbinger KH, Hanus I, Beissner M, Berens-Riba N, Kroidl I, von Sonnenburg F, et al. Lymphocytosis and lymphopenia induced by imported infectious diseases: a controlled cross-sectional study of 17,229 diseased German travelers returning from the Tropics and Subtropics. *Am J Trop Med Hyg* 2016;94(6):1385-91. DOI:10.4269/ajtmh.15-0920.